Idera Pharmaceuticals Inc (Nasdaq:IDRA) Lowers The 52 Week Low

0
22
IDRA daily update
IDRA daily update

Idera Pharmaceuticals Inc (Nasdaq:IDRA)

June 25th, 2018

Amidst falling markets Idera Pharmaceuticals Inc fell $0.16 Monday which equals a 11.11% drop, closing at $1.28. In addition to the drop in value, Idera Pharmaceuticals Inc hit a new 52 week low of $1.27, breaking the previous low of $1.40 from earlier this month. Idera Pharmaceuticals Inc swung 16.54% between low and high. Be aware that the Piotroski Score1 is calculated to be 2, which is very low as the scale goes from 0-9. This is considered to be a weak score in terms of financial strength.

IDRA was outperformed by the rest of the Healthcare sector which went down only 0.90%.

Idera Pharmaceuticals Inc Info

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and nucleic acid chemistry technology. Its drug candidates include IMO-2125, an agonist that is in Phase III clinical trial in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma; and which is in Phase Ib monotherapy trial in multiple tumor types for the treatment of refractory solid tumors, as well as IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. The company is also developing IDRA-008 apolipoprotein C-III gene target for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; nucleic acid chemistry compound for renal target; and IMO-9200 for treating non-malignant gastrointestinal disorders. In addition, it is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GlaxoSmithKline Intellectual Property Development Limited to license, research, develop, and commercialize pharmaceutical compounds from its nucleic acid chemistry technology for the treatment of selected targets in renal disease; Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.

All amounts in USD unless otherwise indicated

(1) The Piotrosky score is used to determine the best value stocks with nine being the best and zero being the worst. It is based on specific aspects of the company’s financial statements, such as positive net income, operating cash flow and asset turnover ratio. A score 0 0 is the worst (Idera Pharmaceuticals Inc’s score is ), and 9 is the best.

IDRA daily update
IDRA daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.